|
1. Ducasse H, Arnal A, Vittecoq M, Daoust S, Ujvari B, Jacqueline C, et al. Cancer: an emergent property of disturbed resource-rich environments? Ecology meets personalized medicine. Evol Appl. 2015; 8(6): 527-40. 2. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005; 14(Suppl 1): 35-48. 3. Hart J. Data support antioxidant use during chemotherapy. Alternative and Complementary Therapies. 2012 Apr, 18(2): 91-97. doi:10.1089/act.2012.18201 4. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr. 2004 Nov;134(11):3201S-3204S. 5. De Vizcaya-Ruiz A, Barbier O, Ruiz-Ramos R, Cebrian ME. Biomarkers of oxidative stress and damage in human populations exposed to arsenic. Mutat Res. 2009 Mar; 674(1-2):85-92. doi:10.1016/j.mrgentox.2008.09.020 6. Moradi M, Divsalar A, Saeidifar M, Saboury A.A, Tahmaseb M. [In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase]. J Fasa Univ Med Sci. 2014; 4(2): 258-67. [Article in Persian] 7. Sen S, Kawahara B, Chaudhuri G. Maintenance of higher H2O2 levels, and its mechanism of action to induce growth in breast cancer cells: important roles of bioactive catalase and PP2A. Free Radic Biol Med. 2012 Oct; 53(8):1541-51. doi:10.1016/j.freeradbiomed.2012.06.030 8. Onumah OE, Jules GE, Zhao Y, Zhou L, Yang H, Guo Z. Overexpression of catalase delays G0/G1- to S-phase transition during cell cycle progression in mouse aortic endothelial cells. Free Radic Biol Med. 2009 Jun; 46(12):1658-67. doi:10.1016/j.freeradbiomed.2009.03.018 9. Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med. 2011 May; 9:62. doi:10.1186/1741-7015-9-62 10. Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, et al. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1082-7. doi:10.1158/1055-9965.EPI-07-2755 11. Petit E, Courtin A, Kloosterboer HJ, Rostène W, Forgez P, Gompel A. Progestins induce catalase activities in breast cancer cells through PRB isoform: correlation with cell growth inhibition. J Steroid Biochem Mol Biol. 2009 Jul;115(3-5):153-60. doi:10.1016/j.jsbmb.2009.04.002 12. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J. Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011 Nov; 82(10):1384-90. doi:10.1016/j.bcp.2011.06.007 13. Kuciel R, Mazurkiewicz A. Formation and detoxification of reactive oxygen species. Biochemistry Mol Biol Edu. 2004; 32(3):183-6. 14. Díaz A, Loewen PC, Fita I, Carpena X. Thirty years of heme catalases structural biology. Arch Biochem Biophys. 2012 Sep; 525(2):102-10. doi:10.1016/j.abb.2011.12.011 15. Loewen PC, Klotz MG, Hassett DJ. Catalase- an old enzyme that continues to surprise us. ASM News. 2000; 66(2): 76-82. 16. Alfonso-Prieto M, Vidossich P, Rovira C. The reaction mechanisms of heme catalases: an atomistic view by ab initio molecular dynamics. Arch Biochem Biophys. 2012 Sep; 525(2):121-30. doi:10.1016/j.abb.2012.04.004 17. Góth L, Nagy T. Acatalasemia and diabetes mellitus. Arch Biochem Biophys. 2012 Sep; 525(2):195-200. doi:10.1016/j.abb.2012.02.005 18. Moradi M, Divsalar A, Saboury AA, Ghalandari B, Harifi AR. Inhibitory effects of deferasirox on the structure and function of bovine liver catalase: a spectroscopic and theoretical study. J Biomol Struct Dyn. 2015; 33(10):2255-66. doi:10.1080/07391102.2014.999353 19. Kwei KA, Finch JS, Thompson EJ, Bowden GT. Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia. 2004 Sep-Oct;6(5):440-8. 20. Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer. 2011 May; 11:191. doi:10.1186/1471-2407-11-191 21. Skrzydlewska E, Kozuszko B, Sulkowska M, Bogdan Z, Kozlowski M, Snarska J, et al. Antioxidant potential in esophageal, stomach and colorectal cancers. Hepatogastroenterology. 2003 Jan-Feb;50(49):126-31. 22. Góth L, Nagy T. Inherited catalase deficiency: is it benign or a factor in various age related disorders? Mutat Res. 2013 Oct-Dec; 753(2): 147-54. doi:10.1016/j.mrrev.2013.08.002 23. Min JY, Lim SO, Jung G. Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter. FEBS Lett. 2010 Jun; 584(11):2427-32. doi:10.1016/j.febslet.2010.04.048 24. Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, et al. A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival. PLoS One. 2015 Aug 24;10(8):e0135739. doi:10.1371/journal.pone.0135739 25. Chung-man Ho J, Zheng S, Comhair SA, Farver C, Erzurum SC. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 2001 Dec; 61(23):8578-85. 26. Stanley JA, Neelamohan R, Suthagar E, Vengatesh G, Jayakumar J, Chandrasekaran M, et al. Lipid peroxidation and antioxidants status in human malignant and non-malignant thyroid tumours. Hum Exp Toxicol. 2015 Aug. pii: 0960327115597982. [Epub ahead of print] 27. Shen Y, Li D, Tian P, Shen K, Zhu J, Feng M, et al. The catalase C-262T gene polymorphism and cancer risk: a systematic review and meta-analysis. Medicine (Baltimore). 2015 Apr; 94(13):e679. doi:10.1097/MD.0000000000000679 28. Kwei KA, Finch JS, Thompson EJ, Bowden GT. Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia. 2004 Sep-Oct; 6(5):440-8. 29. Negahdar M, Djalali M, Abtahi H, Sadeghi MR, Aghvami T, Javadi E, et al. Blood superoxide dismutase and catalase activities in woman affected with breast cancer. Iran J Public Health. 2005; 34(3): 39-43. 30. Yang L, Zheng XL, Sun H, Zhong YJ, Wang Q, He HN, et al. Catalase suppression-mediated H(2)O(2) accumulation in cancer cells by wogonin effectively blocks tumor necrosis factor-induced NF-κB activation and sensitizes apoptosis. Cancer Sci. 2011 Apr;102(4):870-6. doi:10.1111/j.1349-7006.2011.01874.x 31. Ahmed KA, Chinnaiyan P. Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma. Metabolites. 2014 Aug; 4(3):740-50. doi:10.3390/metabo4030740 32. Yousefi R, Saboury AA, Ghadermarzi M, Mossavi-Movahedi AA. Effects of cysteine on the inactivation of bovine liver catalase. Bull Korean Chem Soc. 2000; 21(6): 567-70. 33. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011 Oct; 9:171. doi:10.1186/1479-5876-9-171 34. Rubin H. Cancer cachexia: its correlations and causes. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5384-9. 35. Zhang Zh, Zhao X, Lian J, Guan L, Zhang H. Effect of Iron Supplement on the Activity of Catalase, SDH and Their MRNA Expression in Rex Rabbit. Journal of Animal and Veterinary Advances. 2012; 11:2347-51. doi:10.3923/javaa.2012.2347.2351 36. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. Prostate cancer and physical activity: adaptive response to oxidative stress. Free Radic Biol Med. 2013 Jul; 60:115-24. doi:10.1016/j.freeradbiomed.2013.02.009 37. Akosy Y, Balk M, Ogus H, Ozer N. The mechanism of inhibition of human erythrocyte catalase by azide. Turk J Biol. 2004; 28: 65-70. 38. Kang KA, Lee KH, Chae S, Zhang R, Jung MS, Ham YM, et al. Cytoprotective effect of phloroglucinol on oxidative stress induced cell damage via catalase activation. J Cell Biochem. 2006 Feb; 97(3):609-20. 39. Itsuki-Yoneda A, Kimoto M, Tsuji H, Hiemori M, Yamashita H. Effect of a hypolipidemic drug, Di (2-ethylhexyl) phthalate, on mRNA-expression associated fatty acid and acetate metabolism in rat tissues. Biosci Biotechnol Biochem. 2007 Feb;71(2):414-20. 40. Bolaman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yenisey C, Alper G. The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats. Tohoku J Exp Med. 2005 Dec;207(4):249-53. 41. Labiós M, Martínez M, Gabriel F, Guiral V, Dasi F, Beltrán B, et al. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. J Renin Angiotensin Aldosterone Syst. 2009 Mar;10(1):24-30. doi:10.1177/1470320309104067 42. Ozkan A, Fişkin K. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol. 2004 Jul-Aug; 56(4):435-44. 43. Chi Z, Liu R, Zhang H. Potential enzyme toxicity of oxytetracycline to catalase. Sci Total Environ. 2010 Oct; 408(22):5399-404. doi:10.1016/j.scitotenv.2010.08.005 44. Koohshekan B, Divsalar A, Saeidifar M, Saboury AA. [Side effects of aspirin on the structure and function of liver catalase]. Koomesh. 2014;16(1): 97-102. [Article in Persian] 45. Gholamian A‚ Divsalar A‚ Eslami Moghadam M‚ Saiedifar M, Sabory AA. [The effects of oxali-palladium on the function and structure of liver catalase]. J Arak Univ Med Sci. 2014; 17(2): 40-49. [Article in Persian] 46. Kumaran RS, Choi YK, Singh V, Song HJ, Song KG, Kim KJ, et al. In vitro cytotoxic evaluation of MgO nanoparticles and their effect on the expression of ROS genes]. Int J Mol Sci. 2015; 16(4): 7551-64. doi:10.3390/ijms16047551 47. Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M. Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clin Exp Metastasis. 2006; 23(5-6):269-78. 48. Hyoudou K, Nishikawa M, Ikemura M, Kobayashi Y, Mendelsohn A, Miyazaki N, et al. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J Control Release. 2009 Jul; 137(2):110-5. doi:10.1016/j.jconrel.2009.04.005 49. Galanski M, Yasemi A, Slaby S, Jakupec MA, Arion VB, Rausch M, et al. Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. Eur J Med Chem. 2004 Aug;39(8):707-14. 50. Chen J. Reactive oxygen species and drug resistance in cancer chemotherapy. Austin J Clin Pathol. 2014; 4(1):1-7. 51. Arivarasu NA, Fatima S, Mahmood R. Effect of cisplatin on brush border membrane enzymes and anti-oxidant system of rat intestine. Life Sci. 2007 Jul; 81(5):393-8 52. Divsalar A, Saboury AA, Yousefi R, Moosavi-Movahedi AA, Mansoori-Torshizi H. Spectroscopic and cytotoxic studies of the novel designed palladium(II) complexes: beta-lactoglobulin and K562 as the targets. Int J Biol Macromol. 2007 Mar; 40(4):381-6. 53. Klingelhoeffer C, Kämmerer U, Koospal M, Mühling B, Schneider M, Kapp M, et al. Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med. 2012 May; 12:61. doi:10.1186/1472-6882-12-61 54. Abdollahi M, Shetab-Boushehri SV. Is it right to look for anti-cancer drugs amongst compounds having antioxidant effect? DARU J Pharm Sci. 2012; 20(1): 61. doi:10.1186/2008-2231-20-61
|
